Tazobactam

A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.

Also Known As:

Tazobactam Sodium; YTR 830; YTR 830H; YTR-830; YTR830; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-, 4,4-dioxide, (2S,3S,5R)-

Networked: 241 relevant articles (19 outcomes, 46 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nicolau, David P: 10 articles (12/2021 - 05/2002)
2.	Rhee, Elizabeth G: 7 articles (01/2022 - 01/2019)
3.	Rizk, Matthew L: 5 articles (04/2021 - 01/2019)
4.	Castanheira, Mariana: 4 articles (03/2022 - 06/2013)
5.	Mendes, Rodrigo E: 4 articles (03/2022 - 06/2013)
6.	Bruno, Christopher J: 4 articles (01/2022 - 01/2021)
7.	Feng, Hwa-Ping: 4 articles (01/2022 - 03/2019)
8.	Yu, Brian: 4 articles (01/2022 - 01/2020)
9.	Zhang, Zufei: 4 articles (01/2022 - 01/2020)
10.	Roberts, Jason A: 4 articles (10/2021 - 02/2010)

Related Diseases

1.	Infections 01/01/2017 - "99m Tc-tazobactam, a novel infection imaging agent: Radiosynthesis, quality control, biodistribution, and infection imaging studies." 05/01/1997 - "In view of the tazobactam concentrations in CSF observed in this study, the practice of using a constant concentration of 4 mg of tazobactam per liter for MIC determination is inadequate for intracranial infections. " 10/01/2021 - "We evaluated and compared the roles of tazobactam-based combinations against ESBL-producing organisms with emphasis on pharmacokinetic/pharmacodynamic exposures in relation to MIC distributions and established breakpoints, clinical outcomes data specific to infection site, and considerations for downstream effects with these agents regarding antimicrobial resistance development. " 10/01/2021 - "However, the role of tazobactam-based combinations in treating infections caused by ESBL-producing Enterobacterales remains unclear. " 01/01/2020 - "The percentage of the time that the free drug concentration remains above a concentration threshold (%fT > concentration threshold) has frequently been identified to be the optimal pharmacokinetic (PK)-pharmacodynamic (PD) target of interest for tazobactam using in vitro infection models. "
2.	Urinary Tract Infections (Urinary Tract Infection) 04/01/2016 - "Despite a dearth of new agents currently being developed to combat multidrug-resistant Gram-negative pathogens, the combination of ceftolozane and tazobactam was recently approved by the Food and Drug Administration to treat complicated intra-abdominal and urinary tract infections. " 03/01/2017 - "The target for tazobactam was to achieve a 20% fT > minimum effective concentration (MEC) at an MEC of 1 mg/L, which was derived from a neutropenic mouse thigh infection model and was confirmed by efficacy data from clinical studies for complicated intraabdominal infections and complicated urinary tract infections. " 02/01/2019 - "These results support the safety and efficacy of tazobactam/ceftolozane and suggest it will be a useful treatment for uncomplicated pyelonephritis and complicated urinary tract infection." 03/01/2019 - "Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection." 02/01/2019 - "The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection."
3.	Pyelonephritis 02/01/2019 - "These results support the safety and efficacy of tazobactam/ceftolozane and suggest it will be a useful treatment for uncomplicated pyelonephritis and complicated urinary tract infection." 02/01/2019 - "The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection." 02/01/2002 - "Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections." 02/01/2019 - "We report efficacy and safety results for a combination of a novel cephalosporin class antibiotic and a β-Lactamase inhibitor, tazobactam/ceftolozane (1:2) at a dose of 1.5 g intravenously every 8 h in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. "
4.	Critical Illness (Critically Ill) 03/18/2021 - "Erratum for Kalaria et al., "A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients"." 01/01/2020 - "Traditional tazobactam dosing regimens fail to achieve conservative PK/PD targets in critically ill patients. " 01/01/2020 - "A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients." 01/01/2020 - "The objective of this study was to characterize the tazobactam concentrations in a cohort of critically ill patients with Gram-negative bacterial infections, determine if traditional dosing regimens achieve a prespecified PK/PD target of an 80% fT > concentration threshold of 2 μg/ml, and propose alternative dosing regimens. " 01/01/2022 - "Therefore, the aim of this study was to describe the pharmacokinetics and evaluate different dosing regimens of piperacillin and tazobactam in critically ill patients using an integral population pharmacokinetic model in plasma and urine. "
5.	Pneumonia (Pneumonitis) 01/01/2021 - "The central volumes of distribution for both agents and the peripheral volume of distribution for tazobactam were approximately 2-fold higher in patients with pneumonia compared with healthy participants. " 08/01/2015 - "The addition of tazobactam is intended to broaden coverage to most ESBL-producing Escherichia coli and Klebsiella pneumonia as well as other Enterobacteriaceae. " 04/01/2023 - "CRP, PCT, and ESR levels were related to the severity of pneumonia and were negatively associated with the efficacy of piperacillin and tazobactam. " 03/06/2020 - "The aim of this study was to develop a population pharmacokinetic model for piperacillin (PIPC)/tazobactam (TAZ) in late elderly patients with pneumonia and to optimize the administration planning by applying pharmacokinetic/pharmacodynamic (PK/PD) criteria. " 04/01/2023 - "The patients in the pneumonia group were treated with piperacillin and tazobactam, and the clinical efficacy of CRP, PCT, and ESR levels was analyzed. "

Related Drugs and Biologics

1.	Piperacillin
2.	ceftolozane
3.	beta-Lactamase Inhibitors
4.	Sulbactam
5.	Ceftriaxone (Ceftriaxon)
6.	beta-Lactamases (beta-Lactamase)
7.	Tazobactam Drug Combination Piperacillin (Zosyn)
8.	Anti-Bacterial Agents (Antibiotics)
9.	Cefepime (Maxipime)
10.	Cefotaxime (Kendrick)

Related Therapies and Procedures

1.	Therapeutics
2.	Continuous Renal Replacement Therapy
3.	Intravenous Infusions
4.	Mechanical Ventilators (Ventilator)
5.	Extracorporeal Membrane Oxygenation